TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,701
Mkt Cap
$56.52B
Volume
2.32M
52W High
$17.99
52W Low
$12.99
PE Ratio
72.20
TAK Fundamentals
Price
$17.73
Prev Close
$17.89
Open
$17.71
50D MA
$15.66
Beta
0.24
Avg. Volume
3.44M
EPS (Annual)
$0.2242
P/B
1.16
Rev/Employee
$633,289.19
Loading...
Loading...
News
all
press releases
Takeda Pharmaceutical Co. $TAK Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 25.4% in the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Misses Estimates By $0.07 EPS
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) posted its earnings results on Thursday. The company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates...
MarketBeat·9d ago
News Placeholder
Summit Global Investments Cuts Stock Holdings in Takeda Pharmaceutical Co. $TAK
Summit Global Investments lessened its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 53.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned...
MarketBeat·9d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Saturday...
MarketBeat·10d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Releases FY 2025 Earnings Guidance
Takeda Pharmaceutical (NYSE:TAK) updated its FY 2025 earnings guidance. The company provided EPS guidance of 3.160-3.160 for the period. The company also issued revenue guidance of $29.4...
MarketBeat·10d ago
News Placeholder
Takeda Pharmaceutical Q3 Earnings Call Highlights
Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 third-quarter results that executives said reflected the strength of Takeda fundamentals, supported by disciplined cost management as the company...
MarketBeat·11d ago
News Placeholder
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products...
Business Wire·12d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High - What's Next?
Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week High - Still a Buy...
MarketBeat·14d ago
News Placeholder
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Zacks·18d ago
News Placeholder
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 g/mL IgA in a 10% solution, by prescription...
Business Wire·18d ago
<
1
2
...
>

Latest TAK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.